The historical data trend for PDL BioPharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PDL BioPharma's EV-to-EBIT
For the Biotechnology subindustry, PDL BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDL BioPharma's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDL BioPharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PDL BioPharma's EV-to-EBIT falls into.
PDL BioPharma EV-to-EBIT Calculation
PDL BioPharma's EV-to-EBIT for today is calculated as:
PDL BioPharma's current Enterprise Value is $282.14 Mil.
PDL BioPharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma (NAS:PDLI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PDL BioPharma's Enterprise Value for the quarter that ended in Jun. 2020 was $214.48 Mil.
PDL BioPharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of PDL BioPharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
PDL BioPharma (PDL BioPharma) Business Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PDLI has been successfully added to your 